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Although total knee arthroplasty (TKA) and total hip arthro-
plasty (THA) are effective interventions, their optimal timing 
is unknown. This is illustrated by the varying disease sever-
ity when surgery is performed across centres in Europe and 
Australia (Ackerman et al. 2009, Dieppe et al. 2009). Indica-
tion criteria for TKA/THA in guidelines acknowledge pain, 
function, radiological changes, and insufficient effect of non-
operative therapy (Jordan et al. 2003, Zhang et al. 2005, 2008, 
Gademan et al. 2016). Therefore the first step towards knowl-
edge on optimal timing of TKA/THA is to investigate the time 
course of pain, function, and joint degeneration before surgery. 
Several studies have shown that pain and function in knee 
osteoarthritis (OA) are persistent rather than progressive (Lef-
fondre et al. 2004, Yusuf et al. 2011, Pisters et al. 2012, Collins 
et al. 2014, Wesseling et al. 2015). For example, in our Cohort 
Hip and Cohort Knee (CHECK) consisting of patients with 
pain and/or stiffness of knees and/or hips we showed previ-
ously that 3 stable pain trajectories were found with marginal, 
mild, and moderate pain (Wesseling et al. 2015). Similar 
results have been shown for function (Leffondre et al. 2004, 
Yusuf et al. 2011, Pisters et al. 2012, Riddle et al. 2013, Col-
lins et al. 2014, Wesseling et al. 2015). If pain and function 
in OA are indeed stable and not progressive, optimal timing 
of THA/TKA would depend only on the prosthesis life span 
because the gain after surgery will be equal irrespective of 
timing. However, if the condition is progressive, one would 
expect TKA/THA patients to experience increased pain and 
declining function, particularly in the years before arthro-
plasty. Here gain after surgery may be less if preoperative 
pain/function is worse (Hofstede et al. 2016); patients with 
worse preoperative pain/function tend to have worse outcomes 
although they improve more than patients with fewer preop-
erative complaints. Only 1 previous study investigated trajec-
tories of pain and function before arthroplasty and showed that 
mean pain increased and function decreased during the last 2.5 
Background and purpose — It is unknown whether dif-
ferent trajectories of pain or function are associated with 
timing of total hip or knee arthroplasty (THA/TKA) in osteo-
arthritis (OA) patients. We investigated this association in 
early symptomatic OA patients.
Patients and methods — Data from the prospective 
Dutch CHECK cohort (patients with early hip/knee OA 
complaints) covering 9 years of follow-up were used. Pain 
and function were measured annually using the WOMAC 
questionnaires. Changes in pain/function over time were esti-
mated using a linear mixed model adjusted for baseline age, 
sex, BMI, maximal Kellgren and Lawrence score, number 
of painful joints, and comorbidities. The same covariates 
were included in a Cox regression model, with time to first 
arthroplasty as event. Both were combined in a joint model 
to assess the association between changes in pain/function 
and time to arthroplasty.
Results — Of the 868 eligible patients, 84 received a 
TKA/THA during follow-up. Patients receiving arthroplasty 
were somewhat older, had a higher Kellgren and Lawrence 
score and worse WOMAC scores at baseline. Irrespective 
of receiving arthroplasty, about two-thirds of the patients 
showed at least 1 period of deterioration of pain/function (≥ 
10 points WOMAC subscale). In approximately two fifths 
this deterioration was followed by another deterioration in 
the following year. Worse pain and function levels increased 
the hazard of receiving THA/TKA (1.08 [95% CI 1.06–1.10] 
for pain and 1.07 [CI 1.05–1.08] for function). Changes in 
pain or function over time were not associated with timing 
of THA/TKA
Interpretation — Worse pain and function levels rather 
than long-term changes are associated with timing of THA/
TKA.
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years before surgery (Riddle et al. 2013). However, there was 
no control group, so it is possible that patients not receiving 
arthroplasty reported similar changes in pain/function. 
Therefore, we assessed whether different trajectories of 
pain or function are associated with timing of THA/TKA. To 
answer this question we combined the repeated measurements 
of pain and function among early symptomatic OA patients 
over 9 years, with a time-to-event analysis.  
Patients and methods
Study type and setting
This is a nationwide Dutch observational prospective cohort 
study conducted in cooperation with 10 general and academic 
hospitals located in urbanized and semi-urbanized regions.
Population
A detailed description of the CHECK cohort has been reported 
elsewhere (Wesseling et al. 2014). Eligible patients were 
recruited between 2002 and 2005 and had knee/hip pain, were 
between 45 and 65 years of age and within 6 months of their 
first GP visit for these complaints. There were no radiographic 
signs required to take part in the cohort. Exclusion criteria 
were: any other pathological condition than OA explaining 
the symptoms, comorbidity precluding physical evaluation or 
follow-up of 10 years, malignancy in the past 5 years, and 
inability to understand Dutch. We included 1,002 patients. 
After inclusion, patients were divided into 2 groups: patients 
with relatively more severe symptoms (n = 861, Figure 1, see 
Supplementary data) visited the research centre each year 
for collection of clinical, radiological, and biochemical data; 
patients with mild symptoms (n = 141) visited the research 
centre at years 0, 2, 5, 8, and 10. Patients could shift to the 
more serious symptoms group, and were then measured annu-
ally as well (n = 79 after 5 years) (Wesseling et al. 2014). 
Measurements
Demographics
At baseline patients reported BMI and the number of self-
reported comorbidities according to the Statistics Netherlands 
questionnaire (Botterweck et al. 2001). Self-reported stiffness 
was assessed at baseline using the Western Ontario and McMas-
ter Universities Osteoarthritis Index (WOMAC) stiffness sub-
scale (Bellamy et al. 1988). At baseline, 2, 5, and 8 years knee 
radiographs were taken in a weight-bearing semi-flexed pos-
teroanterior view and for the hip in weight-bearing anteropos-
terior radiographs of the pelvis with hips in 15° internal rota-
tion. Both knee and hip radiographs were read by observers 
blinded to all patient characteristics and the radiographs were 
scored according to Kellgren and Lawrence (K&L). In 38 par-
ticipants radiographs were blindly scored by 5 trained observ-
ers (4 research assistants and 1 experienced general practitioner 
reader) in a paired fashion, with known sequence and interob-
server variability was tested (Cohen’s kappa = 0.60 for K&L ≥ 
2 in knees at 5-year follow-up). The Cohen’s kappa is rather low 
because of the relatively low frequency of radiographic abnor-
malities. Therefore a prevalence-adjusted bias-adjusted kappa 
(PABAK) score was assessed. The PABAK score for reliability 
on progression of OA (KL score) in the knee from 0 to 5 years 
was 0.82, with a 90% average agreement. Similar results were 
found for the hip (Damen et al. 2014).
Pain and function
At baseline, pain history was assessed by a rheumatologist. 
Knee and hip pain were classified as present or absent and the 
total number of painful joints was calculated. Self-reported 
pain and function were assessed at each visit using the 
WOMAC pain/function subscales, each scored on a 5-point 
Likert scale (0 = no pain/good function (Bellamy et al. 1988). 
The pain and function subscales comprise respectively 5 and 
17 questions. 
Arthroplasty
During each visit patients were asked whether they had 
received a TKA/THA. If so, the date of surgery was noted. 
Specific methods current study
We included all measurements until 9 years of follow-up. Only 
patients with at least 2 measurements and no missing values for 
baseline characteristics were included (sex, age, BMI, maximal 
K&L, hip/knee joint pain, and comorbidities) (n = 868, i.e., 
87%). The median follow-up was 9.0 (IQR 8.9–9.1) years. We 
used questionnaire data, data derived by a clinician from medi-
cal records, and radiographical data (Figure 1, see Supplemen-
tary data). Pain and function were assessed by the standardised 
WOMAC pain score ((total pain score) × (100/20)) and func-
tion score ((total function score) × (100/68)). To investigate 
whether THA/TKA patients more often experienced episodes 
of deteriorating pain or function prior to THA/TKA, compared 
with patients not receiving arthroplasty, we defined deteriorat-
ing pain or function as the first ≥ 10 points increase on the 
standardised WOMAC pain/function subscales compared with 
the year before. Further deterioration in the year thereafter 
was defined as any increase in WOMAC pain/function. When 
patients received multiple arthroplasties during follow-up, the 
first arthroplasty was taken as event, and their follow-up was 
censored. Baseline maximal K&L was defined as the highest 
K&L in the hip/knee joints at baseline. Maximal K&L during 
follow-up was defined as the highest K&L in the hip/knee in 
all measurements.
Statistics
Differences in baseline characteristics between patients with 
and without a TKA/THA during follow-up were investigated 
with Student’s t-test (continuous outcomes) or a chi-square 
test (categorical outcomes). To depict the timing of arthroplas-
ties, a Kaplan–Meier curve was estimated.
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Descriptive statistics of the episodes of deterioration were 
reported, e.g., proportion of patients with deterioration of 
pain/function among those with and without arthroplasty. Dif-
ferences between groups were evaluated with logistic regres-
sion adjusted for time to follow-up.
In addition we fitted linear mixed-effects models with a 
random slope and random intercept per patient to the reported 
levels of pain and function. The random-effects part describes 
the time course of pain and function for each patient and takes 
into account the within-subject correlation of different mea-
surements. Within these models we adjusted for age, sex, BMI, 
maximal K&L, number of painful joints, and comorbidities at 
baseline. As such we could estimate the adjusted course of pain 
and function for each patient separately. Pain and function are 
not assumed to be constant between successive measurements, 
so that direct inclusion in a time-dependent Cox model may 
produce biased results. Therefore, we included the estimated 
courses of pain from the linear mixed-effect model (each point 
in time can be estimated with this model) as a time-dependent 
covariate in the Cox model. The latter was done by joint mod-
elling the longitudinal and survival data with the JM package 
(1.4-2) (R version 3.2.3) (Rizopoulos 2010) (Supplementary 
file). We used a piecewise constant baseline hazard. In the Cox 
model we adjusted for age, sex, BMI, maximal K&L, number 
of painful joints, and comorbidities at baseline. 
Sensitivity analysis
We adjusted for maximal K&L during follow-up instead of 
baseline maximal K&L, as radiographic joint deterioration 
is an indication for THA/TKA. Second, we checked whether 
adding the slope of the linear mixed model to the joint model 
changed our results. As the slope refers to the long-term 
change over time in pain/function during 9 years of follow-up, 
we assessed whether these were associated with the likelihood 
of receiving arthroplasty.
Ethics, funding, and potential conflicts of interest 
The medical ethics committees of all participating centres 
approved the study and all patients gave written informed 
consent. This study was funded by CHECK and by a separate 
grant (Dutch Arthritis Foundation (ARGON, BP12-3-401)). 
This foundation did not play a role in the study’s design, con-
duct, or reporting. The authors have no conflicts of interest to 
declare.
Results
Of the 868 included patients, 84 received TKA (n = 29) or 
THA (n = 55) during 9 years of follow-up. Patients receiving 
an arthroplasty were somewhat older at baseline, had higher 
K&L scores, and worse WOMAC scores compared with 
patients without arthroplasty (Table 1). None of the patients 
had a maximal K&L score ≥ 2. Compared with patients not 
included (n = 134), our population had similar baseline char-
acteristics, with the exception of better WOMAC scores (Table 
2, see Supplementary data). Of the 84 arthroplasties, 67 were 
implanted in the first 5 years (Figure 2, see Supplementary 
data). Mean WOMAC scores before arthroplasty were respec-
tively 43.5 (SD 20.6) for function and 45.2 (19.2) for pain. 
Episodes of deterioration of pain and function 
There was no difference in the percentage of patients that 
showed at least 1 period of deterioration of pain between 
patients who did or did not receive TKA/THA during follow-
up: 56/85 patients versus 531/784. 13 of these 56 TKA/THA 
patients showed further deterioration of pain in the year there-
after against 88 of the 531 patients without arthroplasty.
Similar results were found for function; at least 1 period of 
deterioration of function before arthroplasty was found in 56 
of 84 TKA/THA patients and in 540 of 784 patients without 
arthroplasty. This deterioration was followed by further dete-
rioration in the following year in 14 of these 56 the patients 
receiving arthroplasty during follow-up and in 118 of the 540 
patients who did not. 
Hence, there are episodes of deterioration of pain/function in 
patients both with and without arthroplasty. However, patients 
without a prosthesis had more time to develop deterioration 
than patients who received an arthroplasty (median follow-up 
time 9.0 years [IQR 9.0–10.0] versus 4.5 years [IQR 3.3–6.3], 
p < 0.001). When corrected for follow-up duration, arthro-
plasty patients had higher odds on a first deterioration in pain 
Table 1. Baseline patient characteristics of patients who received 
total joint replacement somewhere during follow-up and the 
patients who did not
 Total joint replacement
 No Yes
 n = 784 n = 84 p-value
Age (years) 56 (5.3) 58 (4.3) 0.001
Sex: 
 Male 161 (21) 18 (21)
 Female 623 (80) 66 (79) 0.9
BMI 26 (4.1) 27 (4.6) 0.4
Comorbidities  1.9 (1.5)  1.7 (1.5) 0.3
Number of painful joints:
 1 230 (29) 32 (38)
 2 338 (43) 32 (38)
 3 114 (15) 11 (13)
 4 102 (13)   9 (11) 0.4
Maximal Kellgren and 
 Lawrence score:
 0 291 (37) 11 (13)
 1 493 (63) 73 (87) < 0.001
WOMAC standardized subscales: 
 Pain 24 (16) 33 (19) < 0.001
 Function 22 (17) 32 (17) < 0.001
 Stiffness 32 (21) 38 (20) < 0.01
WOMAC: Western Ontario and McMaster Universities Osteoarthritis 
Index. Continuous variables are shown as mean (SD), categorical 
variables are shown as number (percentage)
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(odds ratio 3.2 [95%CI 1.4–7.2]) and function (odds ratio 2.3 
[CI 1.1–5.0]) than patients without arthroplasty.
Course of pain/ function and timing of arthroplasty
Individual pain and function trajectories are depicted in Figure 
3. Patients had some variation in pain/function levels over 
time (deteriorations were often followed by improvements), 
but overall pain and function seemed to be stable during fol-
low-up as depicted by the plotted line. In accordance with this, 
our adjusted mixed models showed stable pain levels over 
time, –0.1 (CI –0.2 to 0.1) points/year (Table 3), which is –0.5 
points/decade (CI –2.1 to 0.5). Function significantly deterio-
rated over time by 0.3 (CI 0.2–0.4) points/year on a 100-point 
scale (Table 3), which is 2.6 points/decade (CI 1.6–4.2).
The estimates from the joint model showed that higher levels 
on WOMAC score of pain and function significantly increased 
the hazard of receiving THA/TKA (1.08 [CI 1.06–1.10] for 
pain and 1.07 [CI 1.05–1.08] for function) (Table 4).
Sensitivity analysis
Adjusting for maximal K&L during follow-up did not change 
our results (data not shown). When investigating the effect 
of the long-term changes of pain and function over time by 
adding the slope of the initial mixed models, the effect esti-
mates of pain and function levels on receiving THA/TKA 
did not change (Table 5, see Supplementary data), nor did 
the slope itself increase the risk of receiving THA/TKA. The 
wide 95% CIs show that the model could not properly esti-
mate the effect of the slope. Hence, long-term changes in 
pain or function over time did not affect the risk of receiving 
THA/TKA, when adjusted for other covariates and the level 
of pain/function.
Figure 3. Spaghetti plots of the course of pain and function, (left) individual WOMAC pain scores, and (right) 
individual WOMAC function scores. The blue lines represent the mean WOMAC score.
Table 3. Fixed effects of adjusted linear mixed-effects models 
describing the course of pain and function over time
 Estimates for pain Estimates for function
Factor Beta (95% CI) Beta (95% CI)
Time (years) –0.1 (–0.2 to 0.1) 0.3 (0.2 to 0.4)
Sex a 3.8 (1.5 to 6.0) 2.6 (0.3 to 4.9)
Age (years) 0.0 (–0.2 to 0.2) 0.1 (–0.1 to 0.3)
BMI 0.8 (0.6 to 1.0) 0.9 (0.7 to 1.1)
Maximal Kellgren and 
 Lawrence score 1.0 (–0.9 to 2.8) 1.6 (–0.4 to 3.5)
Number of painful joints 2.1 (1.2 to 3.0) 2.4 (1.5 to 3.4)
Comorbidities 2.5 (1.9 to 3.1) 2.8 (2.1 to 3.4)
a Men as reference category
Table 4. Effect estimates of adjusted joint models for total hip and 
knee arthroplasty
 Estimates for pain Estimates for function
Factor HR (95% CI) HR (95% CI)
Pain 1.08 (1.06–1.10)
Function  1.07 (1.05–1.08)
Sex a 0.61 (0.35–1.07) 0.76 (0.44: 1.31)
Age (years) 1.06 (1.01–1.10) 1.05 (1.01–1.10)
BMI 0.94 (0.89–0.99) 0.94 (0.90–1.00)
Maximal Kellgren and 
 Lawrence score 2.96 (1.55–5.67) 2.95 (1.54–5.64)
Number of painful joints 0.73 (0.57–0.93) 0.72 (0.56–0.92)
Comorbidities 0.77 (0.66–0.91) 0.79 (0.68–0.92)
HR = hazard ratio.
a Men as reference category
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Discussion
In this cohort of patients with early OA symptoms at inclu-
sion, we investigated whether pain and function changes 
were associated with receiving THA/TKA. During 9 years of 
follow-up one-tenth of the patients received an arthroplasty. 
Approximately two-thirds of all patients showed at least 1 
episode of deterioration of pain or function during follow-
up. In about one-fifth these deteriorations were followed by 
another deterioration in the following year. At group level, 
pain and function remained fairly stable over time. We showed 
that higher pain and function levels were associated with an 
increased risk of receiving THA/TKA. Adding the individual 
long-term changes in pain or function over time did not affect 
the risk of receiving THA/TKA. Thus, it seems that pain and 
function levels rather than long-term changes are associated 
with timing of THA /TKA. 
At group level, we showed fairly stable levels of pain and 
function over 9 years of follow-up, suggesting that major 
debilitating variables in OA, like pain/functional loss, are per-
sistent rather than worsening. This is in accordance with other 
studies. A study from the Osteoarthritis Initiative identified 5 
relatively stable pain trajectories over 6 years of time in knee 
OA patients (Collins et al. 2014). These trajectories differed 
in severity, but all remained stable during follow-up and none 
showed considerable deterioration/improvement. Recently, in 
the same cohort White et al. (2016) showed 5 different tra-
jectories of function over a period of 7 years. Overall, func-
tion remained stable, although a subgroup of 5% of the cohort 
showed progressive deterioration. However, the mean deterio-
ration was only 13 out of 68 points on the WOMAC scale. A 
different study identified 4 trajectories in total WOMAC score 
in hip/knee OA: increasing scores (18% of the cohort), stable 
(40%), decreasing (24%), and unstable trajectories (18%) 
(Leffondre et al. 2004). Hence, for most patients, trajectories 
remained fairly stable in these studies, although in subgroups 
of patients improvement and deterioration were present. 
The only study investigating trajectories of pain and func-
tion in arthroplasty patients showed that patients tend to 
worsen in function and pain in the last 2 years before arthro-
plasty (Riddle et al. 2013). However, they did not compare 
pain/function trajectories with patients not receiving arthro-
plasty. Our study showed that the long-term change in pain 
and function over time was not associated with arthroplasty, 
and thus not different from those not receiving arthroplasty, 
whereas levels of pain and function were. As patients receiv-
ing an arthroplasty reported worse function and more pain at 
baseline, the levels at which a patient presents him-/herself at 
first visit for OA complaints seem to determine mostly the risk 
of arthroplasty. This conclusion is strengthened by the finding 
that approximately 80% of the arthroplasties were conducted 
within the first 5 years. Moreover we assembled all patients at 
inception of symptoms, implying a rather similar disease stage 
among all patients. As patients receiving THA/TKA showed 
more complaints at baseline than patients not receiving a pros-
thesis, these patients may represent a different patient group. 
One should try to identify this group when commencing clini-
cal care, so that early non-operative treatment can be better 
targeted.
However, besides modelling the natural course of OA, we 
also modelled surgeons’ and patients’ behaviour as they decide 
together that arthroplasty is warranted. If a patient is eager to 
have an arthroplasty he/she has a higher chance of receiving 
it than when the same patient is reluctant. Moreover, some 
surgeons will advise arthroplasty sooner than others. These 
variations might be amplified by the absence of clear indica-
tion criteria for THA/TKA (Ackerman et al. 2009, Dieppe et 
al. 2009, Gademan et al. 2016, Skou et al. 2016, Riddle and 
Perera 2017). As patients receiving arthroplasty may not have 
been the only ones needing arthroplasty, these variations may 
have diluted our analysis, leading to either an under- or an 
overestimation of our effect sizes. Nonetheless, by modelling 
clinical practice, our estimates represent real-life effect sizes. 
Concerning optimal timing of arthroplasty, one could specu-
late that it is beneficial to postpone surgery when possible to 
reduce the risk of revision surgery. Patients with better pre-
operative function attain better postoperative functional levels 
than patients with worse preoperative function (Hofstede et 
al. 2016) but as we showed that patients seem to remain fairly 
stable over time, then lowering the risk of revision surgery 
by postponing the primary surgery might outweigh the risk 
of fast deterioration from a lifetime perspective. Nonetheless, 
no conclusions about timing can be based on this single study 
with early OA patients at baseline. Our results first need to be 
validated in other OA cohorts.
Limitations of our study include that we had no information 
on pharmacological or other non-operative treatment. Dif-
ferent treatment strategies might lead to differences in pain/
function trajectories. However, as THA/TKA is the end-stage 
intervention, both surgeon and patient were convinced that 
THA/TKA was the ultimate treatment option. Furthermore, 
patients were treated according to the Dutch OA guidelines. 
Therefore we expect this to have only small effects on our 
results. Second, patients had early OA symptoms at baseline 
and therefore represent a different patient group than those 
seen by an orthopedic surgeon. This could make our results less 
generalizable to orthopedic practice. However, by the time the 
patients received arthroplasty, they were seen by an orthope-
dic surgeon. Moreover, an advantage of this population is that 
we could assess the course of pain/function from first com-
plaints onwards, giving a complete view of the course of OA 
complaints. Moreover, by including all patients at inception of 
their complaints, selection bias was avoided. Nonetheless our 
results should be validated in another OA population. Third, 
our analysis concerns actual THA/TKA decisions, which may 
not be indicative of optimal THA/TKA decision-making. 
Fourth, often knee and hip OA are reported separately, but in 
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the current study we could not make a such a distinction as 
patients often had both hip and knee complaints. Finally, we 
are aware that adjusting for maximal K&L during follow-up 
is not a statistically preferred method (maximal K&L should 
have been added as a time-varying covariate). However, this 
method would complicate our analysis and the interpretation 
of our results. Furthermore, adjusting for the maximal K&L 
most likely reflects the maximum effect of adjustment.
In summary, pain and function levels rather than long-term 
pain and function changes over time (which can be seen as the 
progression rate) are associated with timing of THA/TKA in 
early OA patients. 
Supplementary data
Tables 2 and 5, and Figures 1–2 are available as supplemen-
tary data in the online version of this article, http://dx.doi.org/
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